P661: JAK2 exon 12-15, CALR and MPL essential MPN NGS panel

P661: JAK2 exon 12-15, CALR and MPL essential MPN NGS panel

Bibliographic Details
Main Authors:	Li Cai, Danny Overman, Carrie Wilson, Binbin Huang, Dan Wang, Ying Wang, Jodie William, Melissa Calvert, Caron Glotzbach, Lauren Kam-Morgan, Anjen Chenn
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Genetics in Medicine Open
Online Access:	http://www.sciencedirect.com/science/article/pii/S294977442400712X

Similar Items

Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR
by: Zhanlong Wang, et al.
Published: (2024-04-01)

PB2176: MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS
by: Marina Stolyar, et al.
Published: (2023-08-01)

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
by: Jerry L. Spivak, et al.
Published: (2021-03-01)

FREQUENCY OF MPL AND JAK2 EXON12 GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
by: Sana Latif, et al.
Published: (2020-06-01)

Prevalence of JAK2 V617F, CALR, and MPL W515L Gene Mutations in Patients with Essential Thrombocythemia in Kurdistan Region of Iraq
by: Bestoon Muhammad Saeed, et al.
Published: (2021-03-01)

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
by: E. Morsia, et al.
Published: (2022-06-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy
by: Morten Orebo Holmström, et al.
Published: (2017-11-01)

A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia
by: Zhuanghui Hao, et al.
Published: (2024-01-01)

Analysis of somatic mutations in the <i>JAK2</i>, <i>CALR</i>, <i>MPL</i> and <i>ASXL1</i> genes and evaluation of their impact on the survival of patients with myelofibrosis
by: T. N. Subbotina, et al.
Published: (2023-03-01)

Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations
by: Jing Wang, et al.
Published: (2023-12-01)

Low <i>JAK2</i> V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional <i>CALR</i> or <i>MPL</i> Gene Mutations
by: Tatiana V. Makarik, et al.
Published: (2021-04-01)

P731: TERT gene promoter region mutation analysis in glioma using multiplex SNaPshot method
by: Li Cai, et al.
Published: (2024-01-01)

Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 <i>CALR</i>-Mutated MPN
by: Ying-Hsuan Wang, et al.
Published: (2023-05-01)

Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis
by: Isabelle Plo, et al.
Published: (2017-09-01)

Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN
by: Jin Zhang, et al.
Published: (2023-06-01)

P984: DIFFERENTIAL IMPACTS OF DISTINCT MUTATION SUBTYPES ON ALTERED S100A8 EXPRESSION AND PHENOTYPIC HETEROGENEITY IN CALR-MUTANT MPN
by: Ying-Ju Chen, et al.
Published: (2023-08-01)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
by: Daniele Cattaneo, et al.
Published: (2021-11-01)

Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
by: Ayesha Gul, et al.
Published: (2022-06-01)

P1029: JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN
by: Jeremy Grevet, et al.
Published: (2023-08-01)

Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.
by: Balligand, T, et al.
Published: (2019)

PB2061: A RARE CASE OF CALR MUTATION IN JAK2-NEGATIVE PATIENT WITH POLYCYTHEMIA
by: T. Subbotina, et al.
Published: (2022-06-01)

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
by: Garima Pandey, et al.
Published: (2022-01-01)

A case of <i>CALR</i> mutation in <i>JAK2</i>-negative patient with polycythemia
by: T. N. Subbotina, et al.
Published: (2022-04-01)

Diagnosis of exon 12‐positive polycythemia vera rescued by NGS
by: Antoine Geay, et al.
Published: (2020-05-01)

Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry
by: Vikas Bhuria, et al.
Published: (2024-03-01)

P1004: ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX
by: Vikas Bhuria, et al.
Published: (2023-08-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)

Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
by: Norton, A, et al.
Published: (2007)

CALR Mutations in Myeloproliferative Neoplasms
by: Ken-Hong Lim
Published: (2014-06-01)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
by: Kathrin Olschok, et al.
Published: (2023-10-01)

MPN Membangun Negara
by: Ishak, Mohamed Mustafa
Published: (2010)

Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms
by: Hejer Elmahmoudi, et al.
Published: (2023-01-01)

c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance
by: Fei Li, et al.
Published: (2022-10-01)

Transcriptomic Analysis Reveals JAK2/MPL-Independent Effects of Calreticulin Mutations in a <i>C. elegans</i> Model
by: Ana Guijarro-Hernández, et al.
Published: (2023-01-01)

The frequency of calreticulin and mpl gene mutations in bcr-abl and jak2 unmutated chronic myeloproliferative neoplasms and its effect on the outcome
by: T. Tiryaki, et al.
Published: (2020-10-01)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
by: Kathrin Olschok, et al.
Published: (2023-08-01)

MPN in the guise of nutritional deficiency
by: Veda P
Published: (2014-08-01)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
by: A. Kaifie, et al.
Published: (2016-03-01)

P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME
by: E. Genovese, et al.
Published: (2022-06-01)